BAUSCH AND LOMB INC
PharmaBAUSCH AND LOMB INC is a pharmaceutical company focused on Ophthalmology, Cardiovascular, Infectious Disease. Key products include PROLENSA.
FDA Novel Drug Designations
(2016-2023)BAUSCH AND LOMB INC's Key Drugs
BAUSCH AND LOMB INC's core commercial portfolio centers on PROLENSA, XIPERE, VYZULTA, spanning Ophthalmology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Inflammation
Macular Edema
Open-Angle Glaucoma
Inflammation
Dry Eye Disease
BAUSCH AND LOMB INC's Recent FDA Approvals
New NDA/BLA approvals for BAUSCH AND LOMB INC over the last two years — novel drugs only, excluding generics and label supplements.
BAUSCH AND LOMB INC's Therapeutic Areas
BAUSCH AND LOMB INC's approved drugs and pipeline span 5 therapeutic areas, led by Ophthalmology and Cardiovascular, across 0 biologic and 21 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BAUSCH AND LOMB INC's Top Competitors
BAUSCH AND LOMB INC's closest competitors by therapeutic-area and drug-target overlap include B BRAUN, BAUSCH, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BAUSCH AND LOMB INC Pipeline Snapshot
Active clinical trials for BAUSCH AND LOMB INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PROLENSA leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Ophthalmology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (8)
Discontinued (0)
Company Info
- First Approval
- 1978-08-17
- Latest
- 2026-01-20
- Applications
- 84